Format
Sort by
Items per page

Send to

Choose Destination

Best matches for ABL1 and Cell Transformation, Neoplastic:

Search results

Items: 1 to 20 of 116

1.

Leukemic Transformation of Myeloproliferative Neoplasms: Therapeutic and Genomic Considerations.

Li B, Mascarenhas JO, Rampal RK.

Curr Hematol Malig Rep. 2018 Dec;13(6):588-595. doi: 10.1007/s11899-018-0491-5. Review.

PMID:
30353413
2.

Economic value of regular monitoring of response to treatment among US patients with chronic myeloid leukemia based on an economic model.

Jabbour EJ, Siegartel LR, Lin J, Lingohr-Smith M, Menges B, Makenbaeva D.

J Med Econ. 2018 Oct;21(10):1036-1040. doi: 10.1080/13696998.2018.1508023. Epub 2018 Aug 15.

PMID:
30071761
3.

Genetic Mutations in a Patient with Chronic Myeloid Leukemia Showing Blast Crisis 10 Years After Presentation.

Sklarz LM, Wittke C, Krohn S, GROßE-Thie C, Junghanss C, Murua Escobar H, Glaeser H.

Anticancer Res. 2018 Jul;38(7):3961-3966. doi: 10.21873/anticanres.12682.

PMID:
29970518
4.

Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia.

Yang H, Chennamaneni LR, Ho MWT, Ang SH, Tan ESW, Jeyaraj DA, Yeap YS, Liu B, Ong EH, Joy JK, Wee JLK, Kwek P, Retna P, Dinie N, Nguyen TTH, Tai SJ, Manoharan V, Pendharkar V, Low CB, Chew YS, Vuddagiri S, Sangthongpitag K, Choong ML, Lee MA, Kannan S, Verma CS, Poulsen A, Lim S, Chuah C, Ong TS, Hill J, Matter A, Nacro K.

J Med Chem. 2018 May 24;61(10):4348-4369. doi: 10.1021/acs.jmedchem.7b01714. Epub 2018 May 7.

PMID:
29683667
5.

Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms.

Mughal TI, Gotlib J, Mesa R, Koschmieder S, Khoury HJ, Cortes JE, Barbui T, Hehlmann R, Mauro M, Saussele S, Radich JP, Van Etten RA, Saglio G, Verstovek S, Gale RP, Abdel-Wahab O.

Leuk Res. 2018 Apr;67:67-74. doi: 10.1016/j.leukres.2018.02.008. Epub 2018 Feb 14. Review.

PMID:
29466766
6.

BCR-ABL1-positive microvesicles malignantly transform human bone marrow mesenchymal stem cells in vitro.

Fu FF, Zhu XJ, Wang HX, Zhang LM, Yuan GL, Chen ZC, Li QB.

Acta Pharmacol Sin. 2017 Nov;38(11):1475-1485. doi: 10.1038/aps.2017.116. Epub 2017 Aug 24.

7.

Hematopoietic stem cell involvement in BCR-ABL1-positive ALL as a potential mechanism of resistance to blinatumomab therapy.

Nagel I, Bartels M, Duell J, Oberg HH, Ussat S, Bruckmueller H, Ottmann O, Pfeifer H, Trautmann H, Gökbuget N, Caliebe A, Kabelitz D, Kneba M, Horst HA, Hoelzer D, Topp MS, Cascorbi I, Siebert R, Brüggemann M.

Blood. 2017 Nov 2;130(18):2027-2031. doi: 10.1182/blood-2017-05-782888. Epub 2017 Aug 21.

8.

Molecular processes involved in B cell acute lymphoblastic leukaemia.

Malouf C, Ottersbach K.

Cell Mol Life Sci. 2018 Feb;75(3):417-446. doi: 10.1007/s00018-017-2620-z. Epub 2017 Aug 17. Review.

9.

SHP2 is required for BCR-ABL1-induced hematologic neoplasia.

Gu S, Sayad A, Chan G, Yang W, Lu Z, Virtanen C, Van Etten RA, Neel BG.

Leukemia. 2018 Jan;32(1):203-213. doi: 10.1038/leu.2017.250. Epub 2017 Aug 14.

10.

Role of NOX2 for leukaemic expansion in a murine model of BCR-ABL1+ leukaemia.

Grauers Wiktorin H, Nilsson T, Aydin E, Hellstrand K, Palmqvist L, Martner A.

Br J Haematol. 2018 Jul;182(2):290-294. doi: 10.1111/bjh.14772. Epub 2017 May 23. No abstract available.

PMID:
28542840
11.

Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer.

Lu H, Villafane N, Dogruluk T, Grzeskowiak CL, Kong K, Tsang YH, Zagorodna O, Pantazi A, Yang L, Neill NJ, Kim YW, Creighton CJ, Verhaak RG, Mills GB, Park PJ, Kucherlapati R, Scott KL.

Cancer Res. 2017 Jul 1;77(13):3502-3512. doi: 10.1158/0008-5472.CAN-16-2745. Epub 2017 May 16.

12.

Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells.

Nieborowska-Skorska M, Sullivan K, Dasgupta Y, Podszywalow-Bartnicka P, Hoser G, Maifrede S, Martinez E, Di Marcantonio D, Bolton-Gillespie E, Cramer-Morales K, Lee J, Li M, Slupianek A, Gritsyuk D, Cerny-Reiterer S, Seferynska I, Stoklosa T, Bullinger L, Zhao H, Gorbunova V, Piwocka K, Valent P, Civin CI, Muschen M, Dick JE, Wang JC, Bhatia S, Bhatia R, Eppert K, Minden MD, Sykes SM, Skorski T.

J Clin Invest. 2017 Jun 1;127(6):2392-2406. doi: 10.1172/JCI90825. Epub 2017 May 8.

13.

Interphase FISH for BCR-ABL1 rearrangement on neutrophils: A decisive tool to discriminate a lymphoid blast crisis of chronic myeloid leukemia from a de novo BCR-ABL1 positive acute lymphoblastic leukemia.

Balducci E, Loosveld M, Rahal I, Boudjarane J, Alazard E, Missirian C, Lafage-Pochitaloff M, Michel G, Zattara H.

Hematol Oncol. 2018 Feb;36(1):344-348. doi: 10.1002/hon.2416. Epub 2017 Apr 25.

PMID:
28444777
14.

TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML.

Valent P, Herndlhofer S, Schneeweiß M, Boidol B, Ringler A, Kubicek S, Gleixner KV, Hoermann G, Hadzijusufovic E, Müllauer L, Sperr WR, Superti-Furga G, Mannhalter C.

Oncotarget. 2017 Apr 4;8(14):23061-23072. doi: 10.18632/oncotarget.15481.

15.

Constitutively active ABL family kinases, TEL/ABL and TEL/ARG, harbor distinct leukemogenic activities in vivo.

Yokota A, Hirai H, Shoji T, Maekawa T, Okuda K.

Leukemia. 2017 Dec;31(12):2742-2751. doi: 10.1038/leu.2017.114. Epub 2017 Apr 7.

PMID:
28386107
16.

Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.

Zhou H, Mak PY, Mu H, Mak DH, Zeng Z, Cortes J, Liu Q, Andreeff M, Carter BZ.

Leukemia. 2017 Oct;31(10):2065-2074. doi: 10.1038/leu.2017.87. Epub 2017 Mar 21.

17.

Cobll1 is linked to drug resistance and blastic transformation in chronic myeloid leukemia.

Han SH, Kim SH, Kim HJ, Lee Y, Choi SY, Park G, Kim DH, Lee A, Kim J, Choi JM, Kim Y, Myung K, Kim H, Kim DW.

Leukemia. 2017 Jul;31(7):1532-1539. doi: 10.1038/leu.2017.72. Epub 2017 Feb 24. Erratum in: Leukemia. 2017 Jul;31(7):1659.

PMID:
28232743
18.

Activation of EVI1 transcription by the LEF1/β-catenin complex with p53-alteration in myeloid blast crisis of chronic myeloid leukemia.

Manachai N, Saito Y, Nakahata S, Bahirvani AG, Osato M, Morishita K.

Biochem Biophys Res Commun. 2017 Jan 22;482(4):994-1000. doi: 10.1016/j.bbrc.2016.11.146. Epub 2016 Nov 28.

PMID:
27908728
19.

Bilineal Extramedullary Blast Crisis as an Initial Presentation of Chronic Myeloid Leukemia: A Case Report and Literature Review.

Gao X, Li J, Wang L, Lin J, Jin H, Xu Y, Wang N, Zhao Y, Liu D, Yu L, Wang Q.

Am J Case Rep. 2016 Oct 27;17:793-798. Review.

20.

Efficient generation and reversion of chromosomal translocations using CRISPR/Cas technology.

Lekomtsev S, Aligianni S, Lapao A, Bürckstümmer T.

BMC Genomics. 2016 Sep 17;17(1):739. doi: 10.1186/s12864-016-3084-5.

Supplemental Content

Loading ...
Support Center